CIPLA's lamivudine cheaper than Glaxo

[James Love <love@cptech.org>]

Does anyone know how these prices compare to Glaxo's US price?  (Also, on a different issue, the US government apparently funded a 3TC invention at Emory University and has
government rights in that drug.)

Here is some information about lamivudine prices that Joe Thomas forwarded to the treatment-access forum.  

jamie


http://www.hivnet.ch:8000/treatment-access/msg?506

Chemists body to take up AIDS drug's selective distribution with Cipla, Glaxo Anju Ghangurde (FINANCIAL EXPRESS, Monday, June 7, 1999) 

Mumbai, June 6: The All India Organisation Of Chemists & Druggists (AIOCD) plans to "discuss" the issue of selective distribution of recently introduced anti-AIDS drug,
lamivudine, with British multinational Glaxo and domestic giant Cipla. 

Glaxo had launched its brand, Epivir (lamivudine), in India last month though Cipla had pipped it to the post with an early launch of its brand, Lamivir, at less than half
the multinational's price. Epivir (150 mg) commands a price of Rs 4,920 (local taxes extra) for 60 tablets, a whopping 146 per cent higher than competitor Cipla's Lamivir
brand costing approximately Rs 2,000 for 60 tablets. 

  [snip]

-- 
James Love, Director, Consumer Project on Technology
I can be reached at love@cptech.org, by telephone 202.387.8030,
by fax at 202.234.5176. CPT web page is http://www.cptech.org